New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

MALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar^® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that New York State Medicaid will begin covering TMS services for adults diagnosed with major depressive disorder (MDD). The coverage will take effect October 1, 2025, for fee-for-service Medicaid members, and November 1, 2025, for those enrolled in Medicaid Managed Care Plans.

Read more at globenewswire.com